Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives
- 31 January 1991
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 90 (1) , 584-589
- https://doi.org/10.1016/0002-9343(91)90633-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.BMJ, 1989
- Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study.Circulation, 1987
- Epidemiology of atherosclerosis: An updated overviewThe American Journal of Cardiology, 1986
- A Prospective Study of Postmenopausal Estrogen Therapy and Coronary Heart DiseaseNew England Journal of Medicine, 1985
- L‐norgestrel and progesterone have different influences on plasma lipoproteinsEuropean Journal of Clinical Investigation, 1983
- Apolipoprotein A-I as a Marker of Angiographically Assessed Coronary-Artery DiseaseNew England Journal of Medicine, 1983
- Estrogen Replacement in the MenopausePublished by American Medical Association (AMA) ,1983
- Effects of Different Progestogens on Lipoproteins during Postmenopausal Replacement TherapyNew England Journal of Medicine, 1981
- ALTERED PLASMA LIPID AND LIPOPROTEIN LEVELS ASSOCIATED WITH ORAL CONTRACEPTIVE AND ŒSTROGEN USE: Report from the Medications Working Group of the Lipid Research Clinics ProgramThe Lancet, 1979
- ARE APOLIPOPROTEINS BETTER DISCRIMINATORS THAN LIPIDS FOR ATHEROSCLEROSIS?The Lancet, 1979